MedTrace Logo

Intra-Articular Allocetra in Patients With Primary Knee Osteoarthritis

NCT07580716 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 270

Last updated 2026-05-20

No results posted yet for this study

Summary

This is a multicenter, randomized, double-blind, placebo-controlled, Phase IIb study to evaluate intra-articular (IA) injections of Allocetra in participants with moderate-to-severe age related symptomatic primary knee osteoarthritis (OA).

Conditions

  • Primary Knee Osteoarthritis

Interventions

DRUG

Allocetra

Allocetra is a cell-based therapy consisting of non-HLA-matched allogeneic peripheral blood mononuclear cells, induced to an apoptotic stable state.

OTHER

Placebo

The control used in this study will be placebo. Placebo solution containing all excipients except for the Allocetra cells.

Sponsors & Collaborators

  • Nordic Bioscience Clinical Development (NBCD)

    collaborator UNKNOWN

  • Enlivex Therapeutics Ltd.

    lead INDUSTRY

Principal Investigators

  • Lital Weinfeld Bergman · Senior Director of Clinical Operations

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
64 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-05-01
Primary Completion
2027-02-28
Completion
2028-04-30
FDA Drug
Yes

Countries

  • United States
  • Denmark
  • Poland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07580716 on ClinicalTrials.gov